

January 28, 2021

The General Manager Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001 Scrip Code: **500770**  The Manager, Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, 5<sup>th</sup> Floor, Plot No.
G Block, Bandra-Kurla Complex
Bandra (E)
Mumbai 400 051
Symbol: TATACHEM

Dear Sir/Madam,

Sub: Outcome of the Board Meeting - January 28, 2021

Ref: <u>Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements)</u> Regulation, 2015 ("Listing Regulations")

This has reference to our letter dated January 18, 2021 giving notice of the Board Meeting to consider the financial results of the Company for the third quarter and nine months ended December 31, 2020.

Pursuant to Regulations 30 and 33 of the Listing Regulations, we wish to inform you that the Board has, today at its meeting, approved the Audited Standalone and Unaudited Consolidated Financial Results of the Company for the third quarter and nine months ended December 31, 2020.

The Meeting of the Board of Directors held today commenced at 2 p.m. and concluded at 5.20 p.m.

A copy of the said Financial Results together with the Auditors' Report/Limited Review Report is enclosed herewith. These are also being made available on the website of the Company at <a href="https://www.tatachemicals.com">www.tatachemicals.com</a>.

The said results shall be published in one English and one vernacular newspaper as required.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For Tata Chemicals Limited

Rajiv Chandan

**General Counsel & Company Secretary** 

Encl: as above

# BSR&Co.LLP

**Chartered Accountants** 

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Telephone: +91 22 6257 1000 Fax: +91 22 6257 1010

Limited Review Report on unaudited quarterly consolidated financial results and consolidated year to date results of Tata Chemicals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

# To the Board of Directors of Tata Chemicals Limited

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Tata Chemicals Limited ("the Parent" or 'the Company') and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its joint ventures for the quarter ended 31 December 2020 and year to date results for the period from 1 April 2020 to 31 December 2020 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
- 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities listed in Annexure I.

Limited Review Report on unaudited quarterly consolidated financial results and consolidated year to date results of Tata Chemicals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

# Tata Chemicals Limited

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of review report of the other auditor referred to in paragraph 7 below nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We draw attention to Note 2(a) of the consolidated financial results in respect of a Scheme of Arrangement amongst the Company and Tata Consumer Products Limited and their respective shareholders and creditors (the 'Scheme') for demerger of Consumer Products Business of the Company. The Scheme had been given effect to in the previous year from the Appointed Date of 1 April 2019 as approved by the National Company Law Tribunal and which is deemed to be the demerger date for the purpose of accounting and consequently financial information in the consolidated financial results for the quarter ended 31 December 2019 and the year to date results for the period from 1 April 2019 to 31 December 2019 had been restated.

Our conclusion is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the Group's share of net profit after tax of Rs.22.03 crores and Rs.57.02 crores and total comprehensive income of Rs.22.03 crores and Rs.57.02 crores for the quarter ended 31 December 2020 and for the period from 1 April 2020 to 31 December 2020 respectively, as considered in the Statement, in respect of a joint venture, whose interim financial information / financial result has not been reviewed by us. This interim financial information/ financial result has been reviewed by another auditor whose report has been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this joint venture, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

8. The Statement includes the interim financial information/ financial results of three subsidiaries which have not been reviewed/audited, whose interim financial information /financial results, after consolidation adjustments, reflect total revenues of Rs. Nil and Rs. Nil, total net profit after tax of Rs. 5.22 crores and Rs.7.96 crores and total comprehensive income of Rs. 5.09 crores and Rs.2.47 crores for the quarter ended 31 December 2020 and for the period from 1 April 2020 to 31 December 2020 respectively, as considered in the Statement.

Limited Review Report on unaudited quarterly consolidated financial results and consolidated year to date results of Tata Chemicals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

# Tata Chemicals Limited

The Statement also includes the Group's share of net loss after tax of Rs. 0.15 crores and Rs. 0.45 crores and total comprehensive loss of Rs. 0.15 crores and Rs.0.45 crores for the quarter ended 31 December 2020 and for the period from 1 April 2020 to 31 December 2020 respectively, as considered in the consolidated unaudited financial results, in respect of two joint ventures, based on their interim financial information/ financial results which have not been reviewed/audited. According to the information and explanations given to us by the management, these interim financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of this matter.

For **B S R & Co. LLP** *Chartered Accountants*Firm's Registration No.101248W/W-100022

VIJAY Digitally signed by VIJAY MATHUR

MATHUR Date: 2021.01.28
17:12:04 +05'30'

Vijay Mathur
Partner
Membership Number: 046476
UDIN: 21046476AAAABF9990

Place: Mumbai Date: 28 January 2021 Limited Review Report on unaudited quarterly consolidated financial results and consolidated year to date results of Tata Chemicals Limited under 33 of the SEBI (Listing Obligations and Disclosure Regulation Requirements) Regulations, 2015 (Continued)

# Tata Chemicals Limited

#### Annexure I

Tata Industries Limited

#### List of entities included in the Statement Name of Entities **Holding Company** Tata Chemicals Limited **Subsidiaries** Tata Chemicals International Pte. Limited 1 2 Rallis India Limited 3 Ncourage Social Enterprise Foundation Step down subsidiaries Homefield Pvt. UK Limited 1 2 TCE Group Limited 3 Natrium Holdings Limited 4 Brunner Mond Group Limited 5 Tata Chemicals Europe Limited 6 Northwich Resource Management Limited Winnington CHP Limited 8 Cheshire Salt Holdings Limited 9 Cheshire Salt Limited 10 **British Salt Limited** 11 Brinefield Storage Limited 12 Cheshire Cavity Storage 2 Limited 13 Cheshire Compressor Limited 14 Irish Feeds Limited 15 New Cheshire Salt Works Limited 16 Tata Chemicals Africa Holdings Limited Tata Chemicals South Africa (Proprietary) Limited 17 18 Tata Chemicals Magadi Limited 19 Magadi Railway Company Limited 20 Gusuite Holdings (UK) Ltd. 21 Valley Holdings Inc 22 Tata Chemicals North America Inc. 23 TCNA (UK) Limited 24 General Chemical International Inc. 25 NHO Canada Holdings Inc. 26 Tata Chemicals (Soda Ash) Partners Holdings 27 Tata Chemicals (Soda Ash) Partners (TCSAP) 28 TCSAP LLC 29 Alcad 30 Rallis Chemistry Exports Limited 31 PT. Metahelix Lifesciences Indonesia **Joint Ventures** 1 The Block Salt Company Limited 2 Joil (S) Pte Ltd 3 Indo Maroc Phosphore S.A.

Regd. Office: Bombay House, 24 Homi Mody Street, Mumbai - 400 001 Statement of Consolidated Financial Results for the quarter and nine months ended 31 December, 2020

Statement of Consolidated Findicial Resolts for the	4			-		(₹ in crore)
Particulars	Quarter ended	Quarter ended	Quarter ended	Nine months ended	Nine months ended	Year ended
	31	30	31	31	31	31
	December,	September,	December, 2019	December, 2020	December, 2019	March, 2020
	2020 (Unaudited)	2020 (Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		,	(note 2(a))	, ,	(note 2(a))	
1 Income a) Revenue from operations (note 6)	2606.08	2609.35	2623.36	7563.59	7978.66	10356.75
b) Other income	42.70	68.55	58.62	169.91	235.57	311.12
Total income (1a + 1b)	2648.78	2677.90	2681.98	7733.50	8214.23	10667.87
2 Expenses a) Cost of materials consumed	515.51	572.70	518.25	1552.67	1447.19	1844.23
b) Purchases of stock-in-trade	72.44	111.45	49.95	236.58	175.22	252.44
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(56.88)	36.64	(52.54)	53.36	(14.17)	(128.27)
d) Employee benefits expense (note 5 (a)) e) Power and fuel	355.68 386.46	352.28 327.24	353.87 375.98	1044.69 998.68	1036.11 1069.47	1375.37 1449.90
f) Freight and forwarding charges	373.42	354.52	379.19	1041.37	1166.79	1551.42
g) Finance costs	80.85	83.63	75.46	282.34	256.40	341.91
h) Depreciation and amortisation expense	185.43 487.54	192.43 468.27	164.11 525.21	567.77 1418.32	492.60 1549.04	666.47 2062.49
i) Other expenses  Total expenses (2a to 2i)	2400.45	2499.16	2389.48	7195.78	7178.65	9415.96
3 Profit before share of profit/(loss) of joint ventures and tax (1-2)	248.33	178.74	292.50	537.72	1035.58	1251.91
4 Share of profit/(loss) of joint ventures (net of tax)	6.19	10.42	(3.90)	15.90	(4.40)	(3.85)
5 Profit before tax (3+4) 6 Tax expenses	254.52	189.16	288.60	553.62	1031.18	1248.06
a) Current tax	54.39	79.67	62.22	181.14	234.21	266.33
b) Deferred tax	(0.59)	(22.60)	5.35	(34.48)	(33.88)	(46.68)
Total tax expenses (6a + 6b) 7 Profit from continuing operations after tax (5-6)	53.80 200.72	57.07 132.09	67.57 221.03	146.66 406.96	200.33 830.85	219.65 1028.41
8 Exceptional (loss)/gain (net) from discontinued operations (note 2(a) and 3)	-	132.07	-	- 406.76	(8.00)	6128.08
9 Share of profit of joint ventures from discontinued operations (net of tax) (note 4)	-	-	-	-	31.34	31.34
10 Tax expense/(release) of discontinued operations (note 2(a))	-	-	20.80	-	60.32	(40.32)
11 (Loss)/profit from discontinued operations after tax (8+9-10) 12 Profit for the period (7+11)	200.72	132.09	(20.80) 200.23	406.96	(36.98) 793.87	6199.74 7228.15
13 Other comprehensive income ('OCI') - gain/(loss)	2002	102.07	200.20	100.70	7.0.07	
a) (i) Items that will not be reclassified to the Consolidated Statement of Profit and Loss						
- Change in fair value of equity investments carried at fair value through OCI     - Remeasurement of defined employee benefit plans	635.62 (38.35)	378.64 50.88	(89.15) (27.12)	1069.21 (101.84)	36.78 (30.06)	(579.88) (68.58)
(ii) Income Tax relating to above items - charge/(reversal)	61.08	48.80	(16.93)	112.69	(0.15)	(95.79)
(iii) Share of other comprehensive income/(loss) of joint ventures (net of tax)	37.82	24.32	45.66	82.28	6.84	(76.39)
b) (i) Items that will be reclassified to the Consolidated Statement of Profit and Loss	0,42	0/20	(/ 4.02)	02/02	(100.53)	(020.77)
- Effective portion of gain/(loss) on cash flow hedges - Changes in foreign currency translation reserve	86.43 (55.85)	86.38 (112.11)	(64.93) (14.82)	236.82 (162.80)	(122.53) 161.22	(230.77) 439.14
(ii) Income Tax relating to above items - charge/(reversal)	(0.78)	4.70	(0.43)	7.50	(4.19)	(4.20)
(iii) Share of other comprehensive income/(loss) of joint ventures (net of tax)	2.26	(3.25)	1.23	(0.36)	3.44	10.19
Total other comprehensive income - gain /(loss) (net of tax) (a(i-ii+iii)+b(i-ii+iii))  14 Total comprehensive income for the period (12+13)	607.63 808.35	371.36 503.45	(131.77) 68.46	1003.12 1410.08	60.03 853.90	(406.30) 6821.85
15 Profit from continuing operations after tax (7)	555.55	300.43	00.40	1410.00	000.70	0021.00
Attributable to:						
Equity shareholders of the Company  Non-controlling interests	160.85 39.87	70.47 61.62	166.97 54.06	244.60 162.36	621.86 208.99	806.59 221.82
Non-connount undesis	200.72	132.09	221.03	406.96	830.85	1028.41
16 (Loss)/profit from discontinued operations after tax (11)						
Attributable to: Equity shareholders of the Company			(20.80)		(36.98)	6199.74
Non-controlling interests	_	_	(20.00)	_	-	-
,	-	-	(20.80)	-	(36.98)	6199.74
17 Profit for the period (12)						
Attributable to: Equity shareholders of the Company	160.85	70.47	146.17	244.60	584.88	7006.33
Non-controlling interests	39.87	61.62	54.06	162.36	208.99	221.82
10 Other comments with income and (flow) ( 1 (1 ) (6)	200.72	132.09	200.23	406.96	793.87	7228.15
18 Other comprehensive income - gain/(loss) (net of tax) (13) Attributable to:						
Equity shareholders of the Company	608.49	370.98	(116.72)	1002.77	24.55	(456.88)
Non-controlling interests	(0.86)	0.38	(15.05)	0.35	35.48	50.58
19 Total comprehensive income for the period (14)	607.63	371.36	(131.77)	1003.12	60.03	(406.30)
Attributable to:						
Equity shareholders of the Company	769.34	441.45	29.45	1247.37	609.43	6549.45
Non-controlling interests	39.01	62.00	39.01	162.71	244.47	272.40
20 Paid-up equity share capital	808.35	503.45	68.46	1410.08	853.90	6821.85
(Face value: ₹ 10 per Share)	254.82	254.82	254.82	254.82	254.82	254.82
21 Other equity and Non-controlling interests						13406.61
22 Earnings per share for continuing operations (in ₹)  - Basic and Diluted	6.31*	2.77*	6.56*	9.60*	24.41*	31.66
23 Earnings per share for discontinued operations (in ₹)	0.01	2.//	0.55	7.00	27.71	31.00
- Basic and Diluted	-	-	(0.82)*	-	(1.45)*	243.36
24 Earnings per share for continuing and discontinued operations (in ₹)	6.31*	2.77*	5.74*	9.60*	22.96*	275.02
- Basic and Diluted  * Not annualised	0.31*	2.//*	5.74*	7.00	22.70"	2/5.02

Quarter ended anded an	Consolidate	ea segmeniwise i	keveliue, kesulis,	Assets and Liabi	ities		(₹ in crore
Segment Revenue	articulars	ended	ended	ended	ended	ended	Year ended
0. Basic chemistry products		2020	2020	2019 (Unaudited)	2020	2019 (Unaudited)	
b. Specialty products 618,34 766.17 604.38 2060.37 1951.28 2328. 2604.93 2604.85 2613.90 7557.95 7666.37 10342. Less: Inter segment revenue 4.34 3.11 3.21 10.13 9.16 10. 2600.59 2601.74 2610.69 7547.82 7957.21 10332. Add: Unallocated 5.49 7.61 12.67 7547.82 7957.21 10332. Total revenue from operations 2606.08 2609.35 2623.36 7563.59 7978.66 10356.  2 Segment Results a. Basic chemistry products 298.12 151.56 327.61 561.35 1001.13 1355. b. Specialty products 38.04 90.48 39.71 221.90 203.67 166. Total segment results 386.16 242.04 367.32 783.25 1204.80 1522. Less: (ii) Finance costs 88.3.3 75.46 282.34 256.40 341. (iii) Net unallocated (income)/expenditure 6.98 (20.33) (0.64) (36.81) (87.18) (71. Profit after exceptional items, before share of profit of joint ventures and tax 248.33 178.74 292.50 537.72 1035.58 1251.  3 Segment Assets 28.0 28.0 28.0 28.0 28.0 28.0 28.0 28.0	Seament Revenue						
Descript products	a. Basic chemistry products	1986.59	1838.68	2009.52	5497.58	6015.09	8013.74
Less: Inter segment revenue						1951.28	2328.85
Less: Inter segment revenue	arepeatan, preases						10342.5
Add: Unallocated 5.49 7.61 12.67 15.77 21.45 24. 10332. Add: Unallocated 5.49 7.61 12.67 15.77 21.45 24. 10332. Add: Unallocated 5.49 7.61 12.67 15.77 21.45 24. 10356. 2606.08 2609.35 2623.36 75563.59 7978.66 10356. 2609.35 2623.36 75563.59 7978.66 10356. 2609.35 2623.36 75563.59 7978.66 10356. 2609.35 2623.36 75563.59 7978.66 10356. 2609.35 2623.36 7563.59 7978.66 10356. 2609.35 2623.36 7563.59 7978.66 10356. 2609.35 2623.36 7563.59 7978.66 10356. 2609.35 2623.36 7563.59 7978.66 10356. 2609.36 2609.36 2609.35 2623.36 7563.59 7978.66 10356. 2609.36 260	Less: Inter seament revenue						10.0
Add: Unallocated 5.49 7.61 12.67 15.77 21.45 24. Total revenue from operations 2606.08 2609.35 2623.36 7563.59 7978.66 10356. 2828.36 7563.59 7978.66 10356. 2828.36 2609.35 2623.36 7563.59 7978.66 10356. 2828.36 2609.35 2623.36 7563.59 7978.66 10356. 2828.36 2609.35 2623.36 7563.59 7978.66 10356. 2828.36 2609.35 2623.36 7563.59 7978.66 10356. 2828.36 2763.29 203.67 166. 2629.29 203.6	2000, 11110, 00 9,1110 11110 0						10332.5
Total revenue from operations   2606.08   2609.35   2623.36   7553.59   7978.66   10356.	Add: Unallocated						24.2
a. Basic chemistry products b. Specialty products costs (i) Finance costs (ii) Finance costs (iii) Net unallocated (income)/expenditure 6.98 20.33 178.74 292.50 20.367 166. 336.16 242.04 367.32 783.25 1204.80 1522. Less: (i) Finance costs (ii) Finance costs (iii) Net unallocated (income)/expenditure 6.98 20.33 20.44 20.45 20.43 20.44 20.45 20.43 20.44 20.45 20.45 20.45 20.33 20.644 20.644 20.645 20.33 20.644 20.646 20.33 20.6466 20.646 20.646 20.646 20.646 20.646 20.646 20.646 20.646 20.6466 20.646 20.646 20.646 20.646 20.646 20.646 20.646 20.646 20.6466 20.646 20.646 20.646 20.646 20.646 20.646 20.646 20.646 20.6466 20.6466 20.6466 20.6466 20.6466 20.6466 20.6466 20.6466 20.64666 20.64666 20.646666 20.6466666666666666666666666666666666666							10356.7
a. Basic chemistry products b. Specialty products costs (ii) Finance costs (iii) Finance costs (iii) Finance costs (iiii) Finance costs							
b. Specialty products Total segment results Less: (i) Finance costs (ii) Finance costs (iii) Net unallocated (income)/expenditure Profit after exceptional items, before share of profit of joint ventures and tax  248.33  178.74  292.50  336.16  242.04  367.32  783.25  1204.80  1522.  1698.26.40  341.  (iii) Net unallocated (income)/expenditure 6.98  (20.33) (0.64) (36.81) (87.18) (71.  Profit after exceptional items, before share of profit of joint ventures and tax  248.33  178.74  292.50  537.72  1035.58  1251.  3 Segment Assets a. Bosic chemistry products 16604.83 16519.25 16259.71 16604.83 16259.71 17150. b. Specialty products 2807.04 2815.08 2755.07 2807.04 2755.07 2804. Add: Unallocated 384.64 7567.37 8228.80 8384.64 8228.80 7734. Add: Unallocated 27776.51 28970.70 27243.58 27796.51 27243.58 27688.  3 Segment Liabilities a. Basic chemistry products 3066.18 2851.41 2800.89 3064.18 2800.89 3064.18 2800.89 3064.18 2800.89 3064.18 2800.89 3064.18 2800.89 3064.18 308.31 308.31 31 31 31 31 31 31 31 31 31 31 31 31 3	_						
Total segment results Less: (ii) Finance costs (iii) Net unallocated (income)/expenditure 6.98 (20.33) (0.54) (36.81) (87.18) (71.  Profit after exceptional items, before share of profit of joint ventures and tax  3 Segment Assets 3							
Less: (i) Finance costs (ii) Net unallocated (income)/expenditure 6,98 (20.33) (0.64) (36.81) (87.18) (71.  Profit after exceptional items, before share of profit of joint ventures and tax  248.33 178.74 292.50 537.72 1035.58 1251.  Segment Assets a. Basic chemistry products b. Specialty products 16604.83 16519.25 16259.71 16604.83 16259.71 17150. b. Specialty products 22807.04 2815.08 2755.07 2807.04 2755.07 2804. Total segment assets 19411.87 19334.33 19014.78 19411.87 19014.78 19954. Add: Unallocated 8384.64 7567.37 8228.80 8384.64 8228.80 7734.  Total assets 27796.51 26901.70 27243.58 27796.51 27243.58 27688.  Segment Liabilities a. Basic chemistry products b. Specialty products 3066.18 2851.41 2800.89 3066.18 2800.89 2893. b. Specialty products 3948.84 3891.77 3688.71 3948.84 3891.77 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3891.77 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3891.77 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3891.77 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3891.77 3688.71 3948.84 3688.71 3948.84 3891.77 3688.71 3948.84 3688.71 3948.84 3891.77 3688.71 3948.84 3891.77 3688.71 3948.84 3688.71 3948.84 3891.77 3688.71 3948.84 3891.77 3688.71 3948.84 3688.71 3948.84 3891.77 3688.71 3948.84 3891.77 3688.7							
(ii) Finance costs (iii) Finance costs (iii) Net unallocated (income)/expenditure 6.98 (20.33) (0.64) (36.81) (87.18) (71.  Profit after exceptional items, before share of profit of joint ventures and tax 248.33 178.74 292.50 537.72 1035.58 1251.  Segment Assets	•	336.16	242.04	367.32	/83.25	1204.80	1522.4
(iii) Net unallocated (income)/expenditure   6.98   (20.33)   (0.64)   (36.81)   (87.18)   (71.57)		80.85	83.63	75.46	282.34	256.40	341 9
Profit after exceptional items, before share of profit of joint ventures and tax  248.33 178.74 292.50 537.72 1035.58 1251.  3 Segment Assets  a. Basic chemistry products 16604.83 16519.25 16259.71 16604.83 16259.71 17150. b. Specialty products 2807.04 2815.08 2755.07 2807.04 2755.07 2804. Total segment assets 19411.87 19334.33 19014.78 19411.87 19014.78 19954. Add: Unallocated 8834.64 7567.37 828.80 8384.64 8228.80 7734.  Total assets 27796.51 26901.70 27243.58 27796.51 27243.58 27688.  3 Segment Liabilities  a. Basic chemistry products 882.66 1040.36 887.82 882.66 887.82 930. Total segment liabilities 3948.84 3891.77 3688.71 3948.84 3688.71 3823. Add: Unallocated 9134.40 9086.64 9525.38 9134.40 9525.38 10203. Total liabilities 13083.24 12978.41 13214.09 13083.24 13214.09 14027.  Information relating to discontinued operations as stated in note 2(a) to the consolidated financial results: Particulars Quarter ended 31 30 31 31 31 31 31 31 31 31 31 31 31 31 31	C7						(71.4
248.33   178.74   292.50   537.72   1035.58   1251.	Profit after exceptional items, before share of profit		(=====)	(212.)	(22.2.)	(5)	(, , , ,
a. Basic chemistry products b. Specialty products 2807.04 2815.08 2755.07 2807.04 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2804. 2755.07 2804. 2755.07 2804. 2755.07 2804. 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2804. 2755.07 2804. 2755.07 2804. 2804. 2807.04 2755.07 2804. 2804. 2807.04 27243.58 27796.51 27243.58 27688.  27688.  2808.61 2808.87 280		248.33	178.74	292.50	537.72	1035.58	1251.9
a. Basic chemistry products b. Specialty products 2807.04 2815.08 2755.07 2807.04 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2804. 2755.07 2804. 2755.07 2804. 2755.07 2804. 2755.07 2804. 2755.07 2807.04 2755.07 2804. 2755.07 2804. 2755.07 2804. 2755.07 2804. 2804. 2807.04 2755.07 2804. 2804. 2807.04 27243.58 27796.51 27243.58 27688.  27688.  2808.61 2808.87 280	Sogmont Assots						
b. Specialty products Total segment assets 19411.87 19334.33 19014.78 19411.87 19014.78 19954. Add: Unallocated 8384.64 7567.37 8228.80 8384.64 8228.80 7734.  Total assets 27796.51 26901.70 27243.58 27796.51 27243.58 27688.  Segment Liabilities a. Basic chemistry products b. Specialty products 5. Specialty products 882.66 1040.36 887.82 882.66 887.82 930. Total segment liabilities 3948.84 3891.77 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3891.77 3688.71 3948.84 3891.77 3688.71 3948.84 3688.71 3948.84 3688.71 3948.84 3891.77 3688.71 3948.84 3891.77 3688.71 3948.84 3688.71 3948.84 3891.77 3688.71 3948.84 3891.7	-	14404 83	14510.25	14250 71	14404.83	14250 71	17150 0
Total segment assets						I .	
Add: Unallocated 8384.64 7567.37 8228.80 8384.64 8228.80 7734.  Total assets 27796.51 26901.70 27243.58 27796.51 27243.58 27688.  3 Segment Liabilities							
Total assets   27796.51   26901.70   27243.58   27796.51   27243.58   27688.	3					I .	
Segment Liabilities   3066.18   2851.41   2800.89   3066.18   2800.89   2893.							
a. Basic chemistry products b. Specialty pro	10101 033013	27770.51	20701.70	27240.50	27770.51	27240.30	27000.7
b. Specialty products	Segment Liabilities						
Total segment liabilities   3948.84   3891.77   3688.71   3948.84   3688.71   3823.	a. Basic chemistry products	3066.18	2851.41	2800.89	3066.18	2800.89	2893.4
Add: Unallocated   9134.40   9086.64   9525.38   9134.40   9525.38   10203.     Total liabilities   13083.24   12978.41   13214.09   13083.24   13214.09   14027.     Information relating to discontinued operations as stated in note 2(a) to the consolidated financial results :   Quarter ended ended ended and an analysis of the state of the ended ended and an analysis of the ended	b. Specialty products	882.66	1040.36	887.82	882.66	887.82	930.1
Total liabilities  13083.24  12978.41  13214.09  13083.24  13214.09  14027.  Information relating to discontinued operations as stated in note 2(a) to the consolidated financial results:  Particulars  Quarter ended ended ended ended ended and and ended	Total segment liabilities	3948.84	3891.77	3688.71	3948.84	3688.71	3823.5
nformation relating to discontinued operations as stated in note 2(a) to the consolidated financial results :  Particulars  Quarter ended ended ended ended ended ended all December, 2020 (Unaudited) Quarter ended endendenendenenenen	Add: Unallocated	9134.40	9086.64	9525.38	9134.40	9525.38	10203.7
Particulars  Quarter ended anded anded anded ended anded ended anded anded ended anded ended anded ended end	Total liabilities	13083.24	12978.41	13214.09	13083.24	13214.09	14027.3
Particulars  Quarter ended anded anded anded ended anded ended anded ended anded ended anded ended end	oformation rolating to discontinued operations as stated	l in noto 2(a) to th	o consolidated fi	inancial rosults :			
2020   2020   2019   2020   2019   2020   (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited)   (Audited)		Quarter ended	Quarter ended	Quarter ended	ended	ended	ended
(Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited)			September,	December,	December,	December,	
		1 2020	2020	2019	2020	2019	2020
		l			!		

#### Notes to the consolidated Financial Results:

1 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 28 January, 2021. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon.

#### 2 Changes in Group structure:

a. In the previous year, upon filing of the certified copies of the NCLT Orders sanctioning the Scheme with the respective jurisdictional Registrar of Companies on 7 February, 2020, the Consumer Products Business Unit ("CPB") is demerged from the Company and transferred to and vested in Tata Consumer Products Limited ("TCPL") with effect from 1 April, 2019 i.e. the Appointed Date. Accordingly, the consolidated financial results for the quarter and nine months ended 31 December, 2019 have been restated.

The difference in the fair value of the demerged undertaking and the carrying amount of net assets of CPB as at 1 April, 2019 is recognised as gain on demerger of CPB in the consolidated financial results as an exceptional item, amounting to ₹ 6,220.15 crore (net of transaction cost) during the year ended 31 March, 2020. Exceptional item for the period ended 31 December, 2019 represents costs relating to the scheme of De-merger.

The Company had recorded tax provision of ₹ 20.80 crore and ₹ 60.32 crore on the profits of CPB for the quarter and nine months ended 31 December, 2019 respectively. This tax provision has been reversed in the quarter ended 31 March, 2020 as it has not been transferred to TCPL post de-merger of CPB.

- b. The Hon'ble National Company Law Tribunal ('NCLT'), Mumbai Bench on 23 April, 2020 approved the Scheme of Merger by Absorption of Bio Energy Venture-1 (Mauritius) Pvt. Ltd. ('Bio'), a wholly owned subsidiary of the Company, by the Company ('Scheme'), with an Appointed Date of 1 April 2019. There is no impact of amalgamation in the consolidated financial results.
- c. During the year ended 31 March, 2020, the Group has acquired the remaining 25% partnership interest from The Andover Group, Inc. in Tata Chemicals (Soda Ash) Partners Holdings for a consideration of ₹ 1,382.12 crore (USD 195 million). With this acquisition, the Group has increased its ownership in Tata Chemicals (Soda Ash) Partners, the soda ash producing operating entity, from 75% to 100%. The resultant difference between the consideration paid and book value of Non Controlling Interest, amounting to ₹ 718.30 crore (net of consequential deferred taxes) has been credited to the retained earnings.
- d. The Hon'ble National Company Law Tribunal (NCLT), Bengaluru Bench and the NCLT, Mumbai Bench have approved the Scheme of Merger ('the Scheme') of Metahelix Life Sciences Limited (wholly owned subsidiary of Rallis India Limited ("Rallis")) into Rallis on 11 November 2019 and 20 December 2019 respectively. Rallis has given effect of the Scheme, which is a common control transaction, in the quarter ended 31 December 2019. The certified copies of the Orders of NCLT Mumbai Bench and NCLT Bengaluru Bench have been filed with the respective Registrar of Companies and accordingly, the Scheme is effective from 1 February 2020 with an Appointed Date of 1 April, 2019. There is no impact of amalgamation in the consolidated financial results.
- e. During the year ended 31 March, 2019, Rallis Chemistry Exports Ltd., a wholly owned subsidiary of Rallis, has made an application to the Registrar of Companies for removal of its name from the register of companies for which the approval is awaited.
- f. The NCLT, Mumbai Bench has approved the Scheme of Merger by Absorption of Zero Waste Agro Organics Limited (wholly-owned subsidiary of Rallis) into Rallis ('the Scheme') on 22 February, 2020 from the appointed date of 1 April, 2017. Rallis has given effect of the Scheme, which was a common control transaction, in the quarter ended 31 March, 2020. The certified copy of the Order is filed with the Registrar of Companies on 9 July, 2020. There is no impact of amalgamation in the consolidated financial results.
- 3 Exceptional items from discontinued operations for the quarter and year ended 31 March, 2020 includes ₹ 92.07 crore in respect of provisions made, relating to the erstwhile fertilizer businesses, as per revised notifications issued by the concerned department for change in rate of subsidy for previous years.
- In the previous year, Share of profit of joint ventures from discontinued operations (net of tax) includes profit arising from sale of one of the subsidiaries of Tata Industries Limited (a joint venture of the Group).

#### Notes to the consolidated Financial Results:

- 5 a. An annual wage settlement pertaining to workmen has resulted in recording of one time charge relating to gratuity benefits of ₹ 14.37 crore in the quarter ended 30 September, 2020.
  - b. The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its valuation once the subject rules are notified and will give appropriate impact in its consolidated financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- 6 During the current quarter, Tata Chemicals Soda Ash Partners, a step-down subsidiary of the Company, has recognised business interruption insurance claim of ₹ 27.18 crore (USD 3.64 million).
- 7 The production of soda ash, sodium bicarbonate and specialty products operations in India has recovered after the initial phases of the lockdown as customers' own operations recommenced.

International businesses operated as normal, adhering to relevant guidelines and safe operating practices. COVID-19 disruptions were generally limited to H1 of FY2020-21. The Group has experienced continuing volume reduction along with reduced prices in the domestic and export markets serviced by its international operations.

The Group has taken into account potential impacts of COVID-19 in the preparation of the consolidated unaudited financial results. Based on the information currently available there is no material impact on carrying amounts of inventories, goodwill, intangible assets, trade receivables, investments and other financial assets though management continue to monitor changes in future economic conditions. The impact of COVID-19 on the consolidated unaudited financial results may differ from that estimated as at the date of approval of these consolidated unaudited financial results.

8 The standalone audited financial results of the Company are available for investors at <a href="https://www.tatachemicals.com">www.tatachemicals.com</a> <a href="https://www.tatachemicals.com">www

As per our report of even date attached For B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W - 100022

VIJAY Digitally signed by VIJAY MATHUR Date: 2021.01.28 17:12:28 +05'30'

Vijay Mathur Partner

Membership No. 046476

Place : Mumbai Date : 28 January, 2021 For and on behalf of TATA CHEMICALS LIMITED

R. Atukundan

Managing Director and CEO

# BSR&Co.LLP

**Chartered Accountants** 

14th Floor, Central Wing, Tower 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai – 400063 Telephone: +91 22 6257 1000 Fax: +91 22 6257 1010

Independent Auditors' Report on Quarterly Standalone Financial Results and Standalone year to date results of Tata Chemicals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Tata Chemicals Limited

Report on the audit of the Standalone Financial Results

#### **Opinion**

We have audited the accompanying standalone quarterly financial results of Tata Chemicals Limited (hereinafter referred to as the "Company") for the quarter ended 31 December 2020 and the standalone year to date results for the period from 1 April 2020 to 31 December 2020, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, these standalone financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards, and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended 31 December 2020 as well as the year to date results for the period from 1 April 2020 to 31 December 2020.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion.

Independent Auditors' Report on Quarterly Standalone Financial Results and Standalone year to date results of Tata Chemicals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

# Tata Chemicals Limited

#### **Emphasis of Matter**

We draw attention to Note 2(b) of the standalone financial results in respect of a Scheme of Arrangement amongst the Company and Tata Consumer Products Limited and their respective shareholders and creditors (the 'Scheme') for demerger of Consumer Products Business of the Company. The Scheme had been given effect to in the previous year from the Appointed Date of 1 April 2019 as approved by the National Company Law Tribunal and which is deemed to be the demerger date for the purpose of accounting and consequently financial information in the standalone financial results for the quarter ended 31 December 2019 and the year to date results for the period from 1 April 2019 to 31 December 2019 had been restated.

Our opinion is not modified in respect of this matter.

#### Management's and Board of Directors' Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the standalone interim financial statements.

The Company's Management and the Board of Directors are responsible for the preparation of these standalone financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Independent Auditors' Report on Quarterly Standalone Financial Results and Standalone year to date results of Tata Chemicals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

# Tata Chemicals Limited

#### Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures
  that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
  effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including
  the disclosures, and whether the standalone financial results represent the underlying transactions
  and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Independent Auditors' Report on Quarterly Standalone Financial Results and Standalone year to date results of Tata Chemicals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

# Tata Chemicals Limited

Auditor's Responsibilities for the Audit of the Standalone Financial Results (Continued)

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

VIJAY Digitally signed by VIJAY MATHUR

MATHUR Date: 2021.01.28
17:12:47 +05'30'

Vijay Mathur

Partner

Membership No: 046476 UDIN: 21046476AAAABE7740

Mumbai 28 January 2021

### Regd. Office: Bombay House, 24 Homi Mody Street, Mumbai - 400 001

Statement of Standalone Audited Financial Results for the quarter and nine months ended 31 December, 2020

(₹ in crore)

Particulars	Quarter ended 31 December, 2020	Quarter ended 30 September, 2020	Quarter ended 31 December, 2019 (Restated) (note 2 (a) and 2 (b))	Nine months ended 31 December, 2020	Nine months ended 31 December, 2019 (Restated) (note 2 (a) and 2 (b))	Year ended 31 March, 2020
1 Income						
a) Revenue from operations	812.24	717.46	759.37	2157.68	2186.24	2920.29
b) Other income	25.89	102.73	34.94	167.15	261.68	309.15
Total Income (1a+1b)	838.13	820.19	794.31	2324.83	2447.92	3229.44
2 Expenses						
a) Cost of materials consumed	186.49	153.89	151.55	424.47	420.17	541.90
b) Purchases of stock-in-trade	38.78	34.41	32.60	106.38	58.13	94.41
c) Changes in inventories of finished goods, work-in-progress and						
stock-in-trade	(16.89)	(2.70)	(27.03)	(0.11)	(74.82)	(76.41)
d) Employee benefits expense (note 4 (a))	59.81	71.14	62.03	189.65	169.71	250.28
e) Power and fuel	136.85	128.02	136.33	362.87	412.01	555.18
f) Freight and forwarding charges	114.25	100.63	95.29	307.33	289.32	390.06
g) Finance costs	4.21	4.48	5.10	13.06	39.52	43.37
h) Depreciation and amortisation expense	48.65	48.78	36.44	144.99	107.94	149.50
i) Other expenses	118.31	115.72	114.10	320.40	334.00	446.83
Total expenses (2a to 2i)	690.46	654.37	606.41	1869.04	1755.98	2395.12
3 Profit before tax (1-2)	147.67	165.82	187.90	455.79	691.94	834.32
4 Tax expenses (note 4)						
a) Current tax	29.07	35.39	42.48	96.26	161.92	194.37
b) Deferred tax	2.96	(4.67)	8.37	0.02	(23.95)	(31.87)
Total tax expenses (4a + 4b)	32.03	30.72	50.85	96.28	137.97	162.50
5 Profit from continuing operations after tax (3-4)	115.64	135.10	137.05	359.51	553.97	671.82
6 Exceptional (loss)/gain (net) from discontinued operations(note 2 (b) and 3)	-	-	-	-	(8.00)	6,128.08
7 Tax expense/(release) of discontinued operations (note 2 (b))	-	-	20.80	-	60.32	(40.32)
8 (Loss)/profit from discontinued operations after tax (6-7)	-	-	(20.80)	-	(68.32)	6168.40
9 Profit for the period (5+8)	115.64	135.10	116.25	359.51	485.65	6840.22
<ul> <li>Other comprehensive income ('OCI') - gain/(loss)</li> <li>(i) Items that will not be reclassified to the Statement of Profit and Loss</li> </ul>						
- Changes in fair value of equity investments carried at fair value through						
OCI	635.58	384.24	(89.14)	1074.58	36.77	(557.31)
<ul> <li>Remeasurement of defined employee benefit plans</li> </ul>	1.74	26.74	(12.13)	17.45	(40.91)	(50.55)
(ii) Income Tax relating to above items - charge/(reversal)	59.34	46.51	(18.60)	105.75	(4.29)	(65.42)
Total other comprehensive income - gain/(loss) (net of tax) (i-ii)	577.98	364.47	(82.67)	986.28	0.15	(542.44)
11 Total comprehensive income for the period (9+10)	693.62	499.57	33.58	1345.79	485.80	6297.78
12 Paid-up equity share capital (Face value: ₹ 10 per share)	254.82	254.82	254.82	254.82	254.82	254.82
<ul><li>13 Other equity</li><li>14 Earnings per share for continuing operations (in ₹)</li></ul>						11722.50
- Basic and Diluted	4.54*	5.30*	5.38*	14.11*	21.75*	26.37
<ul> <li>15 Earnings per share for discontinued operations (in ₹)</li> <li>Basic and Diluted</li> </ul>	_	_	(0.82)*	_	(2.68)*	242.13
16 Earnings per share for continuing and discontinued operations (in ₹)						
- Basic and Diluted	4.54*	5.30*	4.56*	14.11*	19.07*	268.50
* Not annualised						
See annexed segment information and accompanying notes to the standalone financial results						

### Tata Chemicals Limited Standalone Audited Segmentwise Revenue, Results, Assets and Liabilities

(₹ in crore)

Pa	rticulars	Quarter ended 31 December, 2020	Quarter ended 30 September, 2020	Quarter ended 31 December, 2019 (Restated) (note 2 (a) and 2 (b))	Nine months ended 31 December, 2020	Nine months ended 31 December, 2019 (Restated) (note 2 (a) and 2 (b))	Year ended 31 March, 2020
1	Segment Revenue						
	a. Basic chemistry products	764.66	676.50	729.23	2053.25	2133.52	2836.91
	b. Specialty products	47.36	40.89	21.16	104.14	43.74	74.39
	. , ,	812.02	717.39	750.39	2157.39	2177.26	2911.30
	Add: Unallocated	0.22	0.07	8.98	0.29	8.98	8.99
	Total revenue from operations	812.24	717.46	759.37	2157.68	2186.24	2920.29
2	Segment Results						
_	a. Basic chemistry products	179.99	121.42	212.56	460.69	623.50	819.20
	b. Specialty products	(13.86)	(8.85)		(37.82)	(19.06)	(31.99
	Total segment results	166.13	112.57	204.47	422.87	604.44	787.2
	Less:	100.10	2.07	20	.22.07		, 0, 12
	(i) Finance costs	4.21	4.48	5.10	13.06	39.52	43.37
	(ii) Net unallocated expenditure/(income)	14.25	(57.73)	11.47	(45.98)	(127.02)	(90.48
	Total profit before tax	147.67	165.82	187.90	455.79	691.94	834.32
3	Segment Assets						
•	a. Basic chemistry products	2715.46	2729.58	2638.57	2715.46	2638.57	2808.67
	b. Specialty products	564.03	570.02	539.63	564.03	539.63	587.30
	Total segment assets	3279.49	3299.60	3178.20	3279.49	3178.20	3395.97
	Add: Unallocated	11030.77	10214.15	10888.79	11030.77	10888.79	9999.78
	Total assets	14310.26	13513.75	14066.99	14310.26	14066.99	13395.75
4	Segment Liabilities						
-	a. Basic chemistry products	505.37	455.37	655.44	505.37	655.44	650.64
	b. Specialty products	34.71	38.57	24.98	34.71	24.98	39.19
	Total segment liabilities	540.08	493.94	680.42	540.08	680.42	689.83
	Add: Unallocated	727.30	670.55	915.25	727.30	915.25	728.60
	Total liabilities	1267.38	1164.49	1595.67	1267.38	1595.67	1418.43

Particulars	Quarter	Quarter	Quarter	Nine months	Nine months	Year
	ended	ended	ended	ended	ended	ended
	31	30	31	31	31	31
	December,	September,	December,	December,	December,	March,
	2020	2020	2019	2020	2019	2020
			(Restated)		(Restated)	
			(note 2 (a) and		(note 2 (a) and	
			2 (b))		2 (b))	
1 Segment Results (before tax)	-	-	-	-	(8.00)	6,128.08

#### Notes to the standalone financial results:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 28 January, 2021. The same have been audited by the Statutory Auditors who have issued an unqualified opinion thereon.
- 2 a The Hon'ble National Company Law Tribunal ('NCLT'), Mumbai Bench on 23 April, 2020 approved the Scheme of Merger by Absorption of Bio Energy Venture-1 (Mauritius) Pvt. Ltd. ('Bio'), a wholly owned subsidiary of the Company, by the Company ('Scheme'), with an Appointed Date of 1 April 2019. Accordingly, the standalone financial results for the quarter and nine months ended 31 December, 2019 have been restated.
  - b In the previous year, upon filing of the certified copies of the NCLT Orders sanctioning the Scheme with the respective jurisdictional Registrar of Companies on 7 February, 2020, the Consumer Products Business Unit ("CPB") is demerged from the Company and transferred to and vested in Tata Consumer Products Limited ("TCPL") with effect from 1 April, 2019 i.e. the Appointed Date. Accordingly, the standalone financial results for the quarter and nine months ended 31 December, 2019 have been restated.

The difference in the fair value of the demerged undertaking and the carrying amount of net assets of CPB as at 1 April, 2019 is recognised as gain on demerger of CPB in the standalone financial results as an exceptional item, amounting to ₹ 6,220.15 crore (net of transaction cost) during the year ended 31 March, 2020. Exceptional item for the period ended 31 December, 2019 represents costs relating to the scheme of De-merger.

The Company had recorded tax provision of ₹ 20.80 crore and ₹ 60.32 crore on the profits of CPB for the quarter and nine months ended 31 December, 2019 respectively. This tax provision has been reversed in the quarter ended 31 March, 2020 as it has not been transferred to TCPL post de-merger of CPB.

- 3 Exceptional items from discontinued operations for the quarter and year ended 31 March, 2020 includes ₹ 92.07 crore in respect of provisions made, relating to the erstwhile fertilizer businesses, as per revised notifications issued by the concerned department for change in rate of subsidy for previous years.
- 4 a An annual wage settlement pertaining to workmen has resulted in recording of one time charge relating to gratuity benefits of ₹ 14.37 crore in the quarter ended 30 September, 2020.
  - b The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its valuation once the subject rules are notified and will give appropriate impact in its standalone financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- The production of soda ash, sodium bicarbonate and specialty products operations has recovered after the initial phases of the lockdown as customers' own operations recommenced.

The Company has taken into account potential impacts of COVID-19 in the preparation of the standalone financial results. Based on the information currently available there is no material impact on carrying amounts of inventories, goodwill, intangible assets, trade receivables, investments and other financial assets though management continues to monitor changes in future economic conditions. The impact of COVID-19 on the standalone financial results may differ from that estimated as at the date of approval of these standalone financial results.

As per our report of even date attached

For B S R & Co. LLP

**Chartered Accountants** 

Firm's Registration No: 101248W/W - 100022

VIJAY MATHUR Date: 2021.01.28

Date: 2021.01.28 17:13:05 +05'30'

Vijay Mathur

Partner

Membership No. 046476

Place: Mumbai Date: 28 January, 2021 For and on behalf of TATA CHEMICALS LIMITED

∕R. Mukundan

Managing Director and CEO